Advertisement

Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation

  • Shoko Furukawa
  • Keiji NogamiEmail author
  • Kenichi Ogiwara
  • Midori Shima
Original Article

Abstract

Factor VIIa/tissue factor (FVIIa/TF) initiates blood coagulation by promoting FXa generation (extrinsic-Xa). Subsequent generation of intrinsic FXa (intrinsic-Xa) amplifies thrombin formation. Previous studies suggested that FVIIa/TF activates FVIII rapidly in immediate coagulation reactions, and FVIIa/TF/FXa activates FVIII prior to thrombin-dependent feedback. We investigated FVIII/FVIIa/TF/FXa relationships in early coagulation mechanisms. Total FXa generated by FVIIa/TF and FVIIa/TF-activated FVIII (FVIIIaVIIa/TF) was 22.6 ± 1.7 nM (1 min); total FXa with FVIIa-inhibitor was 3.4 ± 0.7 nM, whereas FXa generated by FVIIa/TF or FVIII/TF was 10.4 ± 1.1 or 0.74 ± 0.14 nM, respectively. Little Xa was generated by FVIII alone, suggesting that intrinsic-Xa mechanisms were mediated by FVIIIaVIIa/TF and FVIII/TF in the initiation phase. Intrinsic-Xa was delayed somewhat by von Willebrand factor (VWF). FVIII activation by FXa with FVIIa/TF was comparable to activation with Glu-Gly-Arg-inactivated-FVIIa/TF. TF counteracted the inhibitory effects of VWF on FXa-induced FVIII activation mediated by Arg372 cleavage. The FVIII-C2 domain bound to cytoplasmic domain-deleted TF (TF1−243), and VWF blocked this binding by > 80%, indicating an overlap between VWF- and TF1−243-binding site(s) on C2. Overall, these data suggest that FVIII-associated intrinsic-Xa, governed by both FVIIa/TF-induced and FXa-induced FVIII activation mediated by FVIII-TF interactions, together with FVIIa-dependent extrinsic-Xa mechanisms, may be central to the initiation phase of coagulation.

Keywords

FVIIa Tissue factor FVIII FXa generation Initiation phase 

Notes

Acknowledgements

This work was partly supported by a Grant-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to KN (15K09663 and 18K07885) and by a grand of Bayer Special Project Awards (KN).

Author contributions

SF; performed experiments, interpreted the data, made the figures, and wrote the paper, KN; designed the research, interpreted the data, wrote the paper, edited the manuscript, and approved the final version to be published, KO; performed experiments and interpreted the data, MS; supervised the studies.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

12185_2019_2611_MOESM1_ESM.tiff (8 mb)
Supplementary material 1 (TIFF 8183 KB)
12185_2019_2611_MOESM2_ESM.tiff (8 mb)
Supplementary material 2 (TIFF 8183 KB)

References

  1. 1.
    Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1–16.Google Scholar
  2. 2.
    Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, et al. Structure of human factor VIII. Nature. 1984;312:337–42.CrossRefGoogle Scholar
  3. 3.
    Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330–7.CrossRefGoogle Scholar
  4. 4.
    Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988;263:10451–10445.Google Scholar
  5. 5.
    Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev. 2004;18:1–15.CrossRefGoogle Scholar
  6. 6.
    Eaton D, Rodriguez H, Vehar GA. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505–12.CrossRefGoogle Scholar
  7. 7.
    Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem. 1995;270:8546–52.CrossRefGoogle Scholar
  8. 8.
    Hagen FS, Gray CL, O’Hara P, Grant FJ, Saari GC, Woodbury RG, et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA. 1986;83:2412–6.CrossRefGoogle Scholar
  9. 9.
    Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry. 1990;29:9418–25.CrossRefGoogle Scholar
  10. 10.
    Hoffman M, Monroe DM. rd. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–65.CrossRefGoogle Scholar
  11. 11.
    Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis. 2003;16:17–20.CrossRefGoogle Scholar
  12. 12.
    Klintman J, Astermark J, Berntorp E. Combination of FVIII and bypassing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol. 2010;151:381–6.CrossRefGoogle Scholar
  13. 13.
    Warren DL, Morrissey JH, Neuenschwander PF. Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII cofactor. Biochemistry. 1999;38:6529–36.CrossRefGoogle Scholar
  14. 14.
    Soeda T, Nogami K, Matsumoto T, Ogiwara K, Shima M. Mechanisms of factor VIIa-catalyzed activation of factor VIII. J Thromb Haemost. 2010;8:2494–503.CrossRefGoogle Scholar
  15. 15.
    Yada K, Nogami K, Ogiwara K, Shibata M, Shima M. Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII. Thromb Haemost. 2011;105:989–98.CrossRefGoogle Scholar
  16. 16.
    Yada K, Nogami K, Ogiwara K, Shima M. Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness. J Thromb Haemost. 2013;11:902–10.CrossRefGoogle Scholar
  17. 17.
    Nogami K, Matsumoto T, Yada K, Ogiwara K, Furukawa S, Shida Y, et al. Factor (F)VIII/VIIa enhances global haemostatic function in the co-presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor. Br J Haematol. 2018;181:528–36.CrossRefGoogle Scholar
  18. 18.
    Kamikubo Y, Mendolicchio GL, Zampolli A, Marchese P, Rothmeier AS, Orje JN, et al. Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex. Blood. 2017;130:1661–70.Google Scholar
  19. 19.
    Foster PA, Fulcher CA, Houghten RA, de Graaf Mahoney S, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest. 1988;82:123–8.CrossRefGoogle Scholar
  20. 20.
    Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240–6.CrossRefGoogle Scholar
  21. 21.
    Nogami K, Shima M, Nakai H, Tanaka I, Suzuki H, Morichika S, et al. Identification of a factor VIII peptide, residues 2315–2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect. Br J Haematol. 1999;107:196–203.CrossRefGoogle Scholar
  22. 22.
    Okuda M, Yamamoto Y. Usefulness of synthetic phospholipids in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clin Lab Haematol. 2004;26:215–23.CrossRefGoogle Scholar
  23. 23.
    Nogami K, Wakabayashi H, Schmidt K, Fay PJ. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa. J Biol Chem. 2003;278:1634–41.CrossRefGoogle Scholar
  24. 24.
    Nogami K, Nishiya K, Saenko EL, Takeyama M, Ogiwara K, Yoshioka A, et al. Identification of plasmin-interactive sites in the light chain of factor VIII responsible for proteolytic cleavage at Lys36. J Biol Chem. 2009;284:6934–45.CrossRefGoogle Scholar
  25. 25.
    Takeshima K, Smith C, Tait J, Fujikawa K. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost. 2003;89:788–94.CrossRefGoogle Scholar
  26. 26.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefGoogle Scholar
  27. 27.
    Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol. 1993;222:128–43.CrossRefGoogle Scholar
  28. 28.
    Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem. 1994;269:11601–5.Google Scholar
  29. 29.
    Broze GJ, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed). 2012;17:262–80.CrossRefGoogle Scholar
  30. 30.
    Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123:2934–43.CrossRefGoogle Scholar
  31. 31.
    Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1995;15:2055–62.CrossRefGoogle Scholar
  32. 32.
    Nogami K, Lapan KA, Zhou Q, Wakabayashi H, Fay PJ. Identification of a factor Xa-interactive site within residues 337–372 of the factor VIII heavy chain. J Biol Chem. 2004;279:15763–71.CrossRefGoogle Scholar
  33. 33.
    Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem. 1990;189:229–34.CrossRefGoogle Scholar
  34. 34.
    Nogami K, Shima M, Hosokawa K, Suzuki T, Koide T, Saenko EL, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274:31000–7.CrossRefGoogle Scholar
  35. 35.
    Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipid vesicles. J Biol Chem. 1990;265:815–22.Google Scholar
  36. 36.
    Gajsiewicz JM, Morrissey JH. Structure-function relationship of the interaction between tissue factor and factor VIIa. Semin Thromb Hemost. 2015;41:682–90.CrossRefGoogle Scholar
  37. 37.
    Albert T, Egler C, Jakuschev S, Schuldenzucker U, Schmitt A, Brokemper O, et al. The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis. Thromb Haemost. 2008;99:634–7.CrossRefGoogle Scholar
  38. 38.
    Motton D, Mackman N, Tilley R, Rutledge JC. Postprandial elevation of tissue factor antigen in the blood of healthy adults. Thromb Haemost. 2005;94:504–9.CrossRefGoogle Scholar
  39. 39.
    Nogami K, Shima M, Giddings JC, Takeyama M, Tanaka I, Yoshioka A. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain. Int J Hematol. 2007;85:317–22.CrossRefGoogle Scholar
  40. 40.
    Soeda T, Nogami K, Nishiya K, Takeyama M, Ogiwara K, Sakata Y, et al. The factor VIIIa C2 domain (residues 2228–2240) interacts with the factor IXa Gla domain in the factor Xase complex. J Biol Chem. 2009;284:3379–88.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Shoko Furukawa
    • 1
  • Keiji Nogami
    • 1
    Email author
  • Kenichi Ogiwara
    • 1
  • Midori Shima
    • 1
  1. 1.Department of PediatricsNara Medical UniversityKashiharaJapan

Personalised recommendations